Allarity Therapeutics, Inc.
ALLR Nasdaq Pharmaceutical Preparations Financials FY2020–FY2025
Revenue
Total sales reported in the income statement.
$0.3M
vs prior year
Operating margin
Operating income as a share of revenue.
−3,939.1%
Net income
Profit after all expenses, interest and tax.
−$11.2M
Free cash flow
Cash from operations minus capital spending.
−$14.8M
Return on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
—
Market cap
Last close times the latest diluted share count, so it is approximate.
—
P/E
Last close divided by diluted earnings per share over the last four quarters.
—
What Allarity Therapeutics, Inc. does
No business description yet.
- Legal name
- Allarity Therapeutics, Inc.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 30, 2026
- Accession · CIK
- 0001437749-26-010310
0001860657
Revenue and margins
Allarity Therapeutics, Inc. had $0.3M of revenue in fiscal 2025.
FY20
Revenue —
FY21
Revenue −$1.3M
FY22
Revenue —
FY23
Revenue —
FY24
Revenue $0.0M
FY25
Revenue $0.3M
Q3 '23
Revenue —
Q4 '23
Revenue —
Q1 '24
Revenue —
Q2 '24
Revenue —
Q3 '24
Revenue —
Q4 '24
Revenue —
Q1 '25
Revenue $0.0M
Q2 '25
Revenue $0.0M
Q3 '25
Revenue —
Q4 '25
Revenue —
Q1 '26
Revenue $0.0M
Q2 '26
Revenue $0.0M
FY20
Gross —
Operating —
Net —
FCF —
FY21
Gross —
Operating 1,971.5%
Net 1,978.3%
FCF —
FY22
Gross —
Operating —
Net —
FCF —
FY23
Gross —
Operating —
Net —
FCF —
FY24
Gross —
Operating —
Net —
FCF —
FY25
Gross —
Operating −3,939.1%
Net −3,509.7%
FCF −4,633.8%
Gross
Operating
Net
FCF
Q3 '23
Gross —
Operating —
Net —
FCF —
Q4 '23
Gross —
Operating —
Net —
FCF —
Q1 '24
Gross —
Operating —
Net —
FCF —
Q2 '24
Gross —
Operating —
Net —
FCF —
Q3 '24
Gross —
Operating —
Net —
FCF —
Q4 '24
Gross —
Operating —
Net —
FCF —
Q1 '25
Gross —
Operating —
Net —
FCF —
Q2 '25
Gross —
Operating —
Net —
FCF —
Q3 '25
Gross —
Operating —
Net —
FCF —
Q4 '25
Gross —
Operating —
Net —
FCF —
Q1 '26
Gross —
Operating −10,752.0%
Net −11,000.0%
FCF −18,228.0%
Q2 '26
Gross —
Operating —
Net —
FCF —
Gross
Operating
Net
FCF
Net income and earnings per share
Loss periods are shown in red.
FY20
Net income −$6.6M
FY21
Net income −$26.6M
FY22
Net income −$16.1M
FY23
Net income −$11.9M
FY24
Net income −$24.5M
FY25
Net income −$11.2M
Q3 '23
Net income −$4.4M
Q4 '23
Net income −$1.7M
Q1 '24
Net income −$3.8M
Q2 '24
Net income −$1.6M
Q3 '24
Net income −$11.6M
Q4 '24
Net income −$7.5M
Q1 '25
Net income −$2.7M
Q2 '25
Net income −$2.3M
Q3 '25
Net income −$2.8M
Q4 '25
Net income −$3.4M
Q1 '26
Net income −$2.8M
Q2 '26
Net income −$3.4M
FY20
Diluted EPS —
FY21
Diluted EPS −$4.19
FY22
Diluted EPS −$3,093.42
FY23
Diluted EPS −$10.26
FY24
Diluted EPS —
FY25
Diluted EPS —
Q3 '23
Diluted EPS −$2.03
Q4 '23
Diluted EPS $6,873.36
Q1 '24
Diluted EPS −$22.14
Q2 '24
Diluted EPS −$0.11
Q3 '24
Diluted EPS —
Q4 '24
Diluted EPS —
Q1 '25
Diluted EPS —
Q2 '25
Diluted EPS —
Q3 '25
Diluted EPS —
Q4 '25
Diluted EPS —
Q1 '26
Diluted EPS —
Q2 '26
Diluted EPS —
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
FY20
Return on capital —
Return on equity −27.1%
Return on assets −19.8%
FY21
Return on capital —
Return on equity −125.1%
Return on assets −64.2%
FY22
Return on capital −5,423.5%
Return on equity −178.0%
Return on assets −50.0%
FY23
Return on capital −67,659.6%
Return on equity —
Return on assets −90.1%
FY24
Return on capital —
Return on equity −541.2%
Return on assets −142.1%
FY25
Return on capital —
Return on equity −103.8%
Return on assets −54.9%
Return on capital
Return on equity
Return on assets
Cash flow
Free cash flow was −$14.8M in fiscal 2025, −4,633.8% of revenue. Cash from operations minus capital spending.
FY20
Free cash flow −$7.3M
FY21
Free cash flow —
FY22
Free cash flow −$16.8M
FY23
Free cash flow −$12.7M
FY24
Free cash flow −$17.7M
FY25
Free cash flow −$14.8M
Q3 '23
Free cash flow —
Q4 '23
Free cash flow —
Q1 '24
Free cash flow —
Q2 '24
Free cash flow —
Q3 '24
Free cash flow —
Q4 '24
Free cash flow —
Q1 '25
Free cash flow −$2.7M
Q2 '25
Free cash flow −$5.5M
Q3 '25
Free cash flow —
Q4 '25
Free cash flow —
Q1 '26
Free cash flow −$4.6M
Q2 '26
Free cash flow −$2.6M
FY20
Cash from operations −$7.3M
Capital spending $0.0M
FY21
Cash from operations −$14.9M
Capital spending —
FY22
Cash from operations −$16.8M
Capital spending $0.0M
FY23
Cash from operations −$12.7M
Capital spending $0.0M
FY24
Cash from operations −$17.4M
Capital spending $0.3M
FY25
Cash from operations −$14.8M
Capital spending $0.0M
Cash from operations
Capital spending
Q3 '23
Cash from operations −$5.4M
Capital spending —
Q4 '23
Cash from operations −$1.7M
Capital spending —
Q1 '24
Cash from operations −$1.4M
Capital spending —
Q2 '24
Cash from operations −$7.3M
Capital spending —
Q3 '24
Cash from operations −$5.4M
Capital spending —
Q4 '24
Cash from operations −$3.2M
Capital spending —
Q1 '25
Cash from operations −$2.7M
Capital spending $0.0M
Q2 '25
Cash from operations −$5.5M
Capital spending $0.0M
Q3 '25
Cash from operations −$3.4M
Capital spending —
Q4 '25
Cash from operations −$3.2M
Capital spending —
Q1 '26
Cash from operations −$4.5M
Capital spending $0.1M
Q2 '26
Cash from operations −$2.6M
Capital spending $0.0M
Cash from operations
Capital spending
Dividends, buybacks and share count
Allarity Therapeutics, Inc. returned $3.2M to shareholders in fiscal 2025. The diluted share count rose 0.0%.
FY20
Dividends —
Buybacks —
FY21
Dividends —
Buybacks —
FY22
Dividends —
Buybacks —
FY23
Dividends —
Buybacks —
FY24
Dividends —
Buybacks $0.0M
FY25
Dividends —
Buybacks $3.2M
Dividends
Buybacks
Q3 '23
Dividends —
Buybacks —
Q4 '23
Dividends —
Buybacks —
Q1 '24
Dividends —
Buybacks —
Q2 '24
Dividends —
Buybacks —
Q3 '24
Dividends —
Buybacks $0.0M
Q4 '24
Dividends —
Buybacks $0.0M
Q1 '25
Dividends —
Buybacks $0.0M
Q2 '25
Dividends —
Buybacks $2.6M
Q3 '25
Dividends —
Buybacks $0.1M
Q4 '25
Dividends —
Buybacks $0.5M
Q1 '26
Dividends —
Buybacks $0.3M
Q2 '26
Dividends —
Buybacks $0.0M
Dividends
Buybacks
FY20
Diluted shares 0.00B
FY21
Diluted shares 0.01B
FY22
Diluted shares 0.00B
FY23
Diluted shares 0.00B
FY24
Diluted shares —
FY25
Diluted shares —
Balance sheet
Cash, debt and the ratios that show how comfortably Allarity Therapeutics, Inc. can carry it.
FY20
Cash $0.3M
Debt —
FY21
Cash $19.6M
Debt —
FY22
Cash $2.0M
Debt $2.6M
FY23
Cash $0.2M
Debt $2.9M
FY24
Cash $19.5M
Debt —
FY25
Cash $14.7M
Debt $0.0M
Cash
Debt
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $19.6M | $2.0M | $0.2M | $19.5M | $14.7M |
| Debt incl. finance leases | — | $2.6M | $2.9M | — | $0.0M |
| Debt / equity | — | — | — | — | 0.0x |
| Interest coverage | −268.2x | −154.5x | −34.4x | −41.7x | −68.1x |
| Current ratio | 1.0x | 0.4x | 0.1x | 2.1x | 2.1x |
| Quick ratio | 1.0x | 0.4x | 0.1x | 2.1x | 2.1x |
| Total assets | $49.6M | $14.5M | $11.9M | $22.7M | $18.3M |
| Total liabilities | $30.8M | $12.7M | $14.6M | $10.8M | $8.4M |
| Shareholders' equity | $18.2M | −$0.1M | −$2.8M | $11.8M | $9.8M |
| Net debt (− = net cash) | — | $0.6M | $2.8M | — | −$14.7M |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
| Test | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Net income is positive | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ |
| Cash from operations is positive | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ |
| Return on assets rose | — | ✕ | ✕ | ✓ | ✕ | ✓ |
| Cash from operations exceeds net income | ✕ | ✓ | ✕ | ✕ | ✓ | ✕ |
| Debt fell relative to assets | — | — | — | ✕ | — | — |
| Current ratio rose | — | ✓ | ✕ | ✕ | ✓ | ✓ |
| Share count didn't rise | — | ✕ | ✓ | ✕ | — | — |
| Gross margin rose | — | — | — | — | — | — |
| Revenue rose relative to assets | — | — | — | — | — | ✓ |
| F-score | — / 3 | — / 6 | — / 6 | 1 / 7 | — / 5 | — / 6 |
| Accruals ratio | 1.9% | −28.3% | 2.4% | 6.4% | −41.5% | 17.5% |
| Altman Z'' | −3.45 | −7.25 | −37.26 | −42.60 | −20.73 | −23.25 |
6 years of figures
US$ millions unless stated. Hover a ratio's name for its definition.
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | — | −$1.3M | — | — | $0.0M | $0.3M |
| Net interest income | — | −$1.3M | — | — | — | — |
| Gross profit | — | — | −$2.3M | — | — | — |
| Research and development | $4.2M | $14.2M | $6.9M | $7.1M | $6.1M | $6.6M |
| Operating income | −$8.3M | −$26.6M | −$34.5M | −$17.1M | −$27.2M | −$12.6M |
| Interest expense | $0.1M | $0.1M | $0.2M | $0.5M | $0.7M | $0.2M |
| Pretax income | — | — | −$17.6M | −$11.8M | −$24.9M | −$11.2M |
| Income tax | $0.2M | $0.1M | −$1.5M | $0.1M | −$0.4M | $0.0M |
| Net income | −$6.6M | −$26.6M | −$16.1M | −$11.9M | −$24.5M | −$11.2M |
| Net income to common | −$6.6M | −$26.6M | −$21.1M | −$20.4M | −$25.2M | −$11.2M |
| Diluted EPS | — | −$4.19 | −$3,093.42 | −$10.26 | — | — |
| Diluted shares | 0.00B | 0.01B | 0.00B | 0.00B | — | — |
| Cash flow | ||||||
| Cash from operations | −$7.3M | −$14.9M | −$16.8M | −$12.7M | −$17.4M | −$14.8M |
| Capital expenditure | $0.0M | — | $0.0M | $0.0M | $0.3M | $0.0M |
| Free cash flow | −$7.3M | — | −$16.8M | −$12.7M | −$17.7M | −$14.8M |
| Depreciation and amortization | $0.0M | $0.1M | $0.1M | $0.0M | $0.0M | — |
| Stock-based compensation | $0.6M | $6.4M | $1.8M | −$0.1M | $0.1M | $0.5M |
| Share buybacks | — | — | — | — | $0.0M | $3.2M |
| Dividends and buybacks | — | — | — | — | $0.0M | $3.2M |
| Balance sheet | ||||||
| Cash and short-term investments | $0.3M | $19.6M | $2.0M | $0.2M | $19.5M | $14.7M |
| Total debt | — | — | $2.6M | $2.9M | — | $0.0M |
| Finance lease liabilities | $0.1M | — | — | — | — | — |
| Current assets | $1.7M | $21.4M | $5.0M | $2.0M | $22.3M | $17.9M |
| Current liabilities | $5.5M | $20.7M | $11.2M | $14.2M | $10.8M | $8.4M |
| Property and equipment, net | $0.0M | $0.0M | $0.0M | $0.0M | $0.3M | $0.3M |
| Intangible assets | $30.5M | $28.1M | $9.5M | $9.9M | $0.0M | — |
| Total assets | $33.4M | $49.6M | $14.5M | $11.9M | $22.7M | $18.3M |
| Total liabilities | $9.0M | $30.8M | $12.7M | $14.6M | $10.8M | $8.4M |
| Preferred stock | — | — | $0.0M | $1.7M | $0.0M | — |
| Shareholders' equity | $24.4M | $18.2M | −$0.1M | −$2.8M | $11.8M | $9.8M |
| Margins | ||||||
| Operating margin | — | 1,971.5% | — | — | — | −3,939.1% |
| EBITDA margin | — | 1,963.6% | — | — | — | — |
| Net margin | — | 1,978.3% | — | — | — | −3,509.7% |
| FCF margin | — | — | — | — | — | −4,633.8% |
| Net interest share of revenue | — | 100.0% | — | — | — | — |
| Returns | ||||||
| Return on capital | — | — | −5,423.5% | −67,659.6% | — | — |
| Return on capital employed | −29.8% | −91.8% | −1,037.4% | 743.1% | −230.6% | −128.3% |
| Return on equity | −27.1% | −125.1% | −178.0% | — | −541.2% | −103.8% |
| Return on assets | −19.8% | −64.2% | −50.0% | −90.1% | −142.1% | −54.9% |
| Return on tangible equity | — | — | — | — | −213.0% | −114.3% |
| Growth | ||||||
| Share count change | — | 94.8% | −99.9% | 29,175.0% | — | — |
| Financial health | ||||||
| Debt / equity | — | — | — | — | — | 0.0x |
| Interest coverage | −89.5x | −268.2x | −154.5x | −34.4x | −41.7x | −68.1x |
| Current ratio | 0.3x | 1.0x | 0.4x | 0.1x | 2.1x | 2.1x |
| Quick ratio | 0.3x | 1.0x | 0.4x | 0.1x | 2.1x | 2.1x |
| Capital allocation | ||||||
| Capex / revenue | — | — | — | — | — | 2.5% |
| Stock comp / revenue | — | −472.8% | — | — | — | 150.6% |
| Quality scores | ||||||
| Piotroski F-score | — | — | — | 1.0 | — | — |
| Altman Z'' | −3.4 | −7.3 | −37.3 | −42.6 | −20.7 | −23.2 |
| Accruals ratio | 1.9% | −28.3% | 2.4% | 6.4% | −41.5% | 17.5% |
Source: SEC EDGAR XBRL filings (CIK 0001860657). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.